Mirrahimi Bahador, Moazemi Mahsa, Eslami Narges, Jamshidi Elham, Mir Mahshad, Mohebbi Rezvaneh, Esmaily Hadi
Department of Clinical Pharmacy (BM, HS), School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Student Research Committee (MM, EJ), School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
J Pediatr Pharmacol Ther. 2023;28(1):29-35. doi: 10.5863/1551-6776-28.1.29. Epub 2023 Feb 3.
To evaluate the effects of dietary eicosapentaenoic acid (EPA) in children with atopic dermatitis.
Forty-eight children with atopic dermatitis were randomly allocated to receive either 250 mg twice daily EPA (n = 24) or placebo (n = 24) for 4 weeks. The absolute improvement in the SCORing Atopic Dermatitis (SCORAD) index and the necessity to use topical corticosteroids was evaluated.
Based on an intention-to-treat analysis, after 2 weeks the scores decreased to 30.50 ± 8.91 and 38.34 ± 10.52 in the EPA and placebo groups, respectively (p = 0.015). Per-protocol analysis showed a decrease in scores to 18.01 ± 10.63 in the EPA group and to 30.11 ± 9.58 in the placebo group (p = 0.001). After 2 weeks, corticosteroid was needed in 11 (50.0%) patients in the EPA group and 14 (58.3%) patients in the placebo group (p = 0.571), and after 4 weeks, it was needed in 7 (33.3%) patients in the EPA group and 14 (63.6%) patients in the placebo group, respectively (p = 0.047).
Our results show significant favorable effects of EPA on the SCORAD scale and with regard to the necessity for corticosteroid readministration. Few adverse effects were reported in the 2 groups. We conclude that EPA supplementation is a well-tolerated and effective add-on strategy for reducing the severity of atopic dermatitis in children.
评估膳食中二十碳五烯酸（EPA）对特应性皮炎患儿的影响。
48例特应性皮炎患儿被随机分为两组，一组每日两次服用250毫克EPA（n = 24），另一组服用安慰剂（n = 24），为期4周。评估特应性皮炎评分（SCORAD）指数的绝对改善情况以及使用外用皮质类固醇的必要性。
基于意向性分析，2周后，EPA组和安慰剂组的评分分别降至30.50±8.91和38.34±10.52（p = 0.015）。符合方案分析显示，EPA组评分降至18.01±10.63，安慰剂组降至30.11±9.58（p = 0.001）。2周后，EPA组11例（50.0%）患者需要使用皮质类固醇，安慰剂组14例（58.3%）患者需要使用（p = 0.571）；4周后，EPA组7例（33.3%）患者需要使用，安慰剂组14例（63.6%）患者需要使用，差异有统计学意义（p = 0.047）。
我们的结果显示，EPA在SCORAD量表方面以及再次使用皮质类固醇的必要性方面具有显著的有利影响。两组报告的不良反应均较少。我们得出结论，补充EPA是一种耐受性良好且有效的附加策略，可降低儿童特应性皮炎的严重程度。
